Indraprastha Medical Corporation Ltd vs Pramodini Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Indraprastha Medical Corporation Ltd is ₹ 299.95 as of 23 Oct 15:30 . The P/E Ratio of Indraprastha Medical Corporation Ltd changed from 0 on March 2022 to 0 on March 2026 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2022 to 0 on March 2026 . This represents a CAGR of 0.0% over 5 years The Market Cap of Indraprastha Medical Corporation Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 5 years The revenue of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 414.57 crore as compare to the Mar '26 revenue of ₹ 372.14 crore. This represent the growth of 11.4% The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 88.23 crore as compare to the Mar '26 ebitda of ₹ 67.84 crore. This represent the growth of 30.06% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Indraprastha Medical Corporation Ltd changed from ₹ 44.77 crore to ₹ 55.85 crore over 9 quarters. This represents a CAGR of 10.33% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Indraprastha Medical Corporation Ltd changed from 39.1 % on March 2022 to 19.97 % on March 2026 . This represents a CAGR of -12.57% over 5 yearsThe Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation Limited was incorporated on 16th March, 1988.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis.
The Company was formed as a joint venture between the Government of Delhi and the Apollo Hospitals Group to establish the Indraprastha Apollo Hospitals. The Hospital provides international standard medical care, offering a wide range of multi-specialty services.
Key specialties with strong growth and revenue potential include transplants, cardiology, oncology, neurology, and orthopaedics. The company came out with the public issue of 2,29,18,300 equity shares of Rs 10 each for cash at par aggregating Rs 22,91,83,000.
IMCL is setting up a multi-disciplinary super speciality teritary care referral hospital at New Delhi.

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

FAQs for the comparison of Indraprastha Medical Corporation Ltd and null

Which company has a larger market capitalization, Indraprastha Medical Corporation Ltd or Pramodini Medicare Ltd?

Market cap of Indraprastha Medical Corporation Ltd is 2,749 Cr while Market cap of Pramodini Medicare Ltd is 239 Cr

What are the key factors driving the stock performance of Indraprastha Medical Corporation Ltd and Pramodini Medicare Ltd?

The stock performance of Indraprastha Medical Corporation Ltd and Pramodini Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Indraprastha Medical Corporation Ltd and Pramodini Medicare Ltd?

As of October 25, 2026, the Indraprastha Medical Corporation Ltd stock price is INR ₹299.95. On the other hand, Pramodini Medicare Ltd stock price is INR ₹108.65.

How do dividend payouts of Indraprastha Medical Corporation Ltd and Pramodini Medicare Ltd compare?

To compare the dividend payouts of Indraprastha Medical Corporation Ltd and Pramodini Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.